Journal of Blood & Lymph

Shinichi Ito

Publications

• Research Article
  Rituximab Maintenance Therapy and Bendamustine Containing Treatments may improve the Survival of Mantle Cell Lymphoma: Retrospective Analysis in Single Institute
  Author(s): Ryo Kikuchi, Shinichi Ito, Satomi Matsuoka and Yutaka TsutsumiRyo Kikuchi, Shinichi Ito, Satomi Matsuoka and Yutaka Tsutsumi
  
  Introduction: The prognosis for mantle cell lymphoma (MCL) has remained poor despite the current use of autologous transplantation and induction chemotherapy that includes high-dose cytarabine. The introduction of rituximab and bendamustine, however, has led to the improvement of prognosis of diffuse large B-Cell lymphoma and indolent lymphoma. For these reasons, we analyzed the effectivity of rituximab maintenance therapy and bendamustine against mantle cell lymphoma at our hospital. Methods: We selected 22 cases of MCL for which treatment was initiated between January 2004 and December 2016 at our hospital. We compared the cases based on the use of rituximab maintenance therapy or bendamustine, simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI), staging, and treatment regimens to analyze the effect of rituximab maintenance.. Read More»
  DOI: 10.4172/2165-7831.1000197

  Abstract PDF